Eran Ophir

CEO, Compugen

Search every verified Eran Ophir interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Eran Ophir, president and CEO of Compugen, discussed the company’s AI-driven drug discovery platform and clinical pipeline in a June 2026 podcast interview. He described Compugen’s proprietary computational platform, Unigen, as a validated tool for identifying novel drug targets in cancer immunotherapy, and noted the company’s four clinical-stage programs, including COM701, COM902, rilvegostemig (developed with AstraZeneca under an exclusive license), and GS0321, a potential first ADC. Ophir stated that rilvegostemig, discovered computationally years ago, is close to potential approval, and that COM701 is nearing proof of concept. Ophir also commented on the broader use of AI in drug development, saying that while many companies claim AI capabilities, few have demonstrated tangible value, and that AI is increasingly applied across target discovery, drug design, and adaptive clinical trial design. He highlighted the unique biology of the PVRIG target behind COM701, which he said has shown signals in indications where other checkpoints are less responsive, and estimated an initial patient population of around 10,000 annually for a specific ovarian cancer setting, with potential expansion to earlier lines and other tumor types.